ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.68 USD
0.00 (0.00%)
Updated Sep 24, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 129 | 100 | 222 | 87 | 125 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 63 | 5 | 5 | 3 |
Total Current Assets | 131 | 163 | 227 | 91 | 128 |
Net Property & Equipment | 18 | 17 | 21 | 21 | 3 |
Investments & Advances | 0 | 1 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 149 | 181 | 248 | 113 | 132 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 0 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 3 | 6 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 34 | 18 | 25 | 9 | 11 |
Total Current Liabilities | 37 | 22 | 33 | 12 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 48 | 71 | 17 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5 | 5 | 47 | 18 | 14 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 104 | 112 | 114 | 48 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 4 | 4 | 2 | 2 |
Capital Surplus | 447 | 435 | 471 | 330 | 322 |
Retained Earnings | -434 | -401 | -376 | -294 | -237 |
Other Equity | 28 | 31 | 35 | 27 | 18 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 45 | 69 | 134 | 65 | 105 |
Total Liabilities & Shareholder's Equity | 149 | 181 | 248 | 113 | 132 |
Total Common Equity | 45 | 69 | 134 | 65 | 105 |
Shares Outstanding | 81.30 | 80.80 | 71.20 | 50.20 | 49.70 |
Book Value Per Share | 0.55 | 0.85 | 1.88 | 1.29 | 2.11 |
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 104 | 112 | 129 | 131 | 140 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 2 | 5 | 3 |
Total Current Assets | 110 | 116 | 131 | 136 | 143 |
Net Property & Equipment | 18 | 18 | 18 | 19 | 18 |
Investments & Advances | 0 | 0 | 0 | 0 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 127 | 134 | 149 | 155 | 161 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 5 | 5 | 0 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 34 | 31 | 34 | 25 | 20 |
Total Current Liabilities | 40 | 37 | 37 | 29 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 38 | 45 | 48 | 56 | 61 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 5 | 3 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 92 | 97 | 104 | 104 | 105 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 4 | 4 | 4 | 4 |
Capital Surplus | 445 | 448 | 447 | 449 | 450 |
Retained Earnings | -442 | -443 | -434 | -431 | -427 |
Other Equity | 29 | 29 | 28 | 28 | 30 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 35 | 38 | 45 | 50 | 56 |
Total Liabilities & Shareholder's Equity | 127 | 134 | 149 | 155 | 161 |
Total Common Equity | 35 | 38 | 45 | 50 | 56 |
Shares Outstanding | 81.30 | 81.30 | 81.30 | 80.80 | 80.80 |
Book Value Per Share | 0.44 | 0.47 | 0.55 | 0.62 | 0.70 |